Drugs / MVA-mBN32
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00428337 | Apr 2007 → Aug 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00386633 Comparator | Oct 2006 → Nov 2007 | HIV infectious disease | Bavarian Nordic | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00390078 Comparator | Jan → Dec 2007 | HIV infectious disease | Bavarian Nordic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-mBN32 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00390078 ↗ |
| Modality | Vaccine | “epitope-based vaccine MVA-mBN32” NCT00386633 ↗ |